Music |
Video |
Movies |
Chart |
Show |
Adjuvant treatment with sorafenib or sunitinib doesn't improve outcomes in localised renal carcinoma (ecancer) View |
Implications of using adjuvant sorafenib and sunitinib in unfavourable renal carcinoma (ecancer) View |
Frontline Sunitinib Compared to Everolimus in Metastatic Renal Cell Carcinoma (OncLive) View |
HCC: Managing Patients on Frontline Systemic Therapy (OncLive) View |
Adjuvant Treatment of RCC—Part 1 (PracticeUpdate) View |
Assessing Response to Sorafenib (OncLive) View |
BTTC Everolimus/Sorafenib Study (National Cancer Institute) View |
Current Data on RCC Therapy: Sunitinib Dosing, Combination Therapy and More (PracticeUpdate) View |
Mayer Fishman, MD, Ph.D. (GoodNewsBroadcast) View |
Strategies for Managing VEGF-TKI Toxicities (Targeted Oncology) View |